Advisor - Neurodegenerative Diagnostics

At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our 35,000 employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We're looking for people who are determined to make life better for people around the world.

Organization Overview:

At Lilly, we serve an extraordinary purpose. We make a difference for people around the globe by discovering, developing and delivering medicines that help them live longer, healthier, more active lives. Not only do we deliver breakthrough medications, but you also can count on us to develop creative solutions to support communities through philanthropy and volunteerism.

Position Overview:

Are you looking to be part of an organization that is developing and expanding diagnostics to enable better diagnosis and treatment of neurodegenerative disorders? Lilly's Neuroscience Research team is committed to developing cutting-edge novel diagnostics and therapies and is seeking inspiring scientists to join our team. The Diagnostic Advisor role will drive the development of novel diagnostics and improvement of existing diagnostics.

Responsibilities:

• Provide strategic and technical input on the development, implementation and quantitative evaluation of diagnostic blood-based biomarkers and emerging markers (such as CNS derived exosomes) in drug development projects for neurodegenerative conditions (Alzheimer's Disease, Parkinson's Disease, rare types of dementia)
• Design and implement customized diagnostic analysis (segmentation, registration, abnormality characterization) pipelines, leveraging between novel strategies and standard methodologies.
• Lead the development of emerging diagnostic technologies with a strong focus on exosome biomarker research
• Execute pre-clinical studies to assess pathogenic diagnostics and treatment response biomarkers
• Collaborate cross-functionally with internal research and clinical (medical, operations, statistics, regulatory) teams as well as external CROs to support the validation of diagnostic biomarkers and their application in therapeutic development.
• Communicate, present and publish results of research projects and clinical trials as appropriate.

Basic Qualifications:

• PhD in Neuroscience or related field
• Extensive knowledge of blood-based diagnostics, analysis and interpretation

Additional Skills/Preferences:

• Post doc and/or industry research in exosome biomarker research strongly preferred
• Proven analytical and problem-solving skills
• Excellent communication, listening, writing and interpersonal skills
• Demonstrated learning agility, critical thinking and negotiation skills
• Strong interpersonal and leadership skills
• Demonstrated ability to work independently as well as in highly integrated cross-functional teams

Eli Lilly and Company, Lilly USA, LLC and our wholly owned subsidiaries (collectively "Lilly") are committed to help individuals with disabilities to participate in the workforce and ensure equal opportunity to compete for jobs. If you require an accommodation to submit a resume for positions at Lilly, please email Lilly Human Resources ( [email protected] ) for further assistance. Please note This email address is intended for use only to request an accommodation as part of the application process. Any other correspondence will not receive a response.

Lilly is an EEO/Affirmative Action Employer and does not discriminate on the basis of age, race, color, religion, gender, sexual orientation, gender identity, gender expression, national origin, protected veteran status, disability or any other legally protected status.

As a condition of employment with Eli Lilly and Company and its subsidiaries in the United States and Puerto Rico, you must be fully COVID-19 vaccinated and provide proof of vaccination satisfactory to the company (subject to applicable law).